House dust mite sublingual immunotherapy is safe in patients with mild-to-moderate, persistent asthma: a clinical trial

Title
House dust mite sublingual immunotherapy is safe in patients with mild-to-moderate, persistent asthma: a clinical trial
Authors
Keywords
-
Journal
ALLERGY
Volume 71, Issue 2, Pages 249-257
Publisher
Wiley
Online
2015-10-14
DOI
10.1111/all.12791

Ask authors/readers for more resources

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation